Analysts await Coherus BioSciences, Inc. (NASDAQ:CHRS) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-1.42 EPS, down 14.08% or $0.2 from last year’s $-1.22 per share.

At the moment 4 analysts are watching Coherus BioSciences, Inc. (NASDAQ:CHRS), 0 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 1 analyst has a mean sales target of 30.00 million. For the quarter ending Sep-16, 1 analyst has a mean sales target of 35.00 million whilst for the year ending Dec-16, 4 analysts have a mean target of 34.50 million.

In terms of earnings per share, 1 analyst has a -1.37 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 1 analyst has a -1.36 EPS mean target and for the quarter ending Sep-16 there are 4 estimates of -5.84 EPS.

The biggest institutional shareholders in Coherus BioSciences, Inc. include Fidelity Management and Research Company which owns 5 million shares in the company valued at $116.88 million. Kohlberg Kravis Roberts & Co. L.P. is the second biggest holder with 3 million shares currently valued at 93.42 million whilst Lilly Ventures Fund I LLC has 3 million shares valued at 93.02 million.

Total shares held by institutions as of the most recent company filings are 33,487,277 with a reported 2,538,174 bought and 1,032,727 sold. These holdings make up 85.6% of the company’s outstanding shares.

Currently insiders hold 413,923 shares in the business which makes up 1.08% of shares. The biggest holder currently is Dr. Alan C. Herman, PhD who owns 206,615 shares (0.53% of those outstanding), whilst Dennis M. Lanfear holds 71,635 (0.18% of shares outstanding) and Mr. Christos Richards holds 63,836 (0.16% of shares outstanding).

The stock increased 3.45% or $0.64 during the last trading session.